Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1988 May;85(9):3184–3188. doi: 10.1073/pnas.85.9.3184

Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.

S R Hanson 1, L A Harker 1
PMCID: PMC280168  PMID: 3362867

Abstract

Since the antithrombin action of heparin fails to interrupt arterial thrombosis, a mediating role for thrombin (EC 3.4.21.5) in the formation of high-shear platelet-dependent thrombus has been unproven. To determine whether thrombin is important in acute arterial thrombus formation and to assess the therapeutic potential of inhibiting its action, the effects of the synthetic covalent antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (FPRCH2Cl) on arterial-flow vascular graft thrombosis and occlusion have been studied in a nonhuman primate model. Continuous intravenous infusion of FPRCH2Cl (100 nmol/kg per min) into vascular graft-bearing baboons (Papio anubis) abolished (i) vascular graft 111In-platelet deposition, (ii) vascular graft occlusion, (iii) thrombus-associated in vivo release of platelet-specific proteins and fibrinopeptides, (iv) platelet hemostatic plug formation, (v) thrombin-induced platelet aggregation ex vivo, and (vi) thrombin-induced blood clotting. The effects of FPRCH2Cl largely disappeared within 15 min after the infusion had been discontinued. FPRCH2Cl produced no detectable cardiovascular or other acute side effects. In contrast, sustained comparably anticoagulating levels of heparin had no effect upon 111In-platelet graft deposition, graft occlusion, platelet function as measured by the bleeding time, platelet aggregation ex vivo, or release of platelet-specific proteins in vivo. We conclude that thrombin is the principal mediator of platelet-dependent hemostatic plug formation and of the formation of platelet-dependent high-flow acute graft thrombosis and occlusion. Moreover, FPRCH2Cl or other synthetic antithrombins may provide effective antithrombotic therapy for both arterial and venous thrombosis by simultaneously inhibiting platelet activation and fibrin formation.

Full text

PDF
3184

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bock P. E., Luscombe M., Marshall S. E., Pepper D. S., Holbrook J. J. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J. 1980 Dec 1;191(3):769–776. doi: 10.1042/bj1910769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cimo P. L., Moake J. L., Weinger R. S., Ben-Menachem Y. B., Khalil K. G. Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses. Am J Hematol. 1979;6(2):125–133. doi: 10.1002/ajh.2830060204. [DOI] [PubMed] [Google Scholar]
  3. Collen D., Matsuo O., Stassen J. M., Kettner C., Shaw E. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med. 1982 Jan;99(1):76–83. [PubMed] [Google Scholar]
  4. Hanson S. R., Harker L. A., Bjornsson T. D. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest. 1985 May;75(5):1591–1599. doi: 10.1172/JCI111865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hanson S. R., Harker L. A. Studies of suloctidil in experimental thrombosis in baboons. Thromb Haemost. 1985 Jun 24;53(3):423–427. [PubMed] [Google Scholar]
  6. Hanson S. R., Kotze H. F., Savage B., Harker L. A. Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis. 1985 Nov-Dec;5(6):595–603. doi: 10.1161/01.atv.5.6.595. [DOI] [PubMed] [Google Scholar]
  7. Hanson S. R., Pareti F. I., Ruggeri Z. M., Marzec U. M., Kunicki T. J., Montgomery R. R., Zimmerman T. S., Harker L. A. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest. 1988 Jan;81(1):149–158. doi: 10.1172/JCI113286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Harker L. A., Hanson S. R. Experimental arterial thromboembolism in baboons. Mechanism, quantitation, and pharmacologic prevention. J Clin Invest. 1979 Aug;64(2):559–560. doi: 10.1172/JCI109494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Harker L. A., Malpass T. W., Branson H. E., Hessel E. A., 2nd, Slichter S. J. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980 Nov;56(5):824–834. [PubMed] [Google Scholar]
  10. Harker L. A., Slichter S. J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med. 1972 Jul 27;287(4):155–159. doi: 10.1056/NEJM197207272870401. [DOI] [PubMed] [Google Scholar]
  11. Harmon J. T., Jamieson G. A. Activation of platelets by alpha-thrombin is a receptor-mediated event. D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone-thrombin, but not N alpha-tosyl-L-lysine chloromethyl ketone-thrombin, binds to the high affinity thrombin receptor. J Biol Chem. 1986 Dec 5;261(34):15928–15933. [PubMed] [Google Scholar]
  12. Harmon J. T., Jamieson G. A. The glycocalicin portion of platelet glycoprotein Ib expresses both high and moderate affinity receptor sites for thrombin. A soluble radioreceptor assay for the interaction of thrombin with platelets. J Biol Chem. 1986 Oct 5;261(28):13224–13229. [PubMed] [Google Scholar]
  13. Hauptmann J., Markwardt F. Studies on the anticoagulant and antithrombotic action of an irreversible thrombin inhibitor. Thromb Res. 1980 Nov 1;20(3):347–351. doi: 10.1016/0049-3848(80)90238-8. [DOI] [PubMed] [Google Scholar]
  14. Kaiser B., Markwardt F. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors. Thromb Res. 1986 Sep 15;43(6):613–620. doi: 10.1016/0049-3848(86)90098-8. [DOI] [PubMed] [Google Scholar]
  15. Kettner C., Shaw E. D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin. Thromb Res. 1979;14(6):969–973. doi: 10.1016/0049-3848(79)90014-8. [DOI] [PubMed] [Google Scholar]
  16. Lindhout T., Baruch D., Schoen P., Franssen J., Hemker H. C. Thrombin generation and inactivation in the presence of antithrombin III and heparin. Biochemistry. 1986 Oct 7;25(20):5962–5969. doi: 10.1021/bi00368a019. [DOI] [PubMed] [Google Scholar]
  17. Markwardt F. Pharmacological approaches to thrombin regulation. Ann N Y Acad Sci. 1986;485:204–214. doi: 10.1111/j.1749-6632.1986.tb34582.x. [DOI] [PubMed] [Google Scholar]
  18. McManus L. M., Hanahan D. J., Pinckard R. N. Human platelet stimulation by acetyl glyceryl ether phosphorylcholine. J Clin Invest. 1981 Mar;67(3):903–906. doi: 10.1172/JCI110108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Morinelli T. A., Niewiarowski S., Kornecki E., Figures W. R., Wachtfogel Y., Colman R. W. Platelet aggregation and exposure of fibrinogen receptors by prostaglandin endoperoxide analogues. Blood. 1983 Jan;61(1):41–49. [PubMed] [Google Scholar]
  20. Nieuwenhuis H. K., Akkerman J. W., Houdijk W. P., Sixma J. J. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature. 1985 Dec 5;318(6045):470–472. doi: 10.1038/318470a0. [DOI] [PubMed] [Google Scholar]
  21. Okamoto S., Hijikata A., Kikumoto R., Tonomura S., Hara H., Ninomiya K., Maruyama A., Sugano M., Tamao Y. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun. 1981 Jul 30;101(2):440–446. doi: 10.1016/0006-291x(81)91279-1. [DOI] [PubMed] [Google Scholar]
  22. Salzman E. W., Rosenberg R. D., Smith M. H., Lindon J. N., Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980 Jan;65(1):64–73. doi: 10.1172/JCI109661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Savage B., McFadden P. R., Hanson S. R., Harker L. A. The relation of platelet density to platelet age: survival of low- and high-density 111indium-labeled platelets in baboons. Blood. 1986 Aug;68(2):386–393. [PubMed] [Google Scholar]
  24. Schaeffer R. C., Jr, Briston C., Chilton S. M., Carlson R. W. Disseminated intravascular coagulation following Echis carinatus venom in dogs: effects of a synthetic thrombin inhibitor. J Lab Clin Med. 1986 Jun;107(6):488–497. [PubMed] [Google Scholar]
  25. Schaeffer R. C., Jr, Chilton S. M., Hadden T. J., Carlson R. W. Pulmonary fibrin microembolism with Echis carinatus venom in dogs: effects of a synthetic thrombin inhibitor. J Appl Physiol Respir Environ Exerc Physiol. 1984 Dec;57(6):1824–1828. doi: 10.1152/jappl.1984.57.6.1824. [DOI] [PubMed] [Google Scholar]
  26. Todd M. E., McDevitt E., Goldsmith E. I. Blood-clotting mechanisms of nonhuman primates. Choice of the baboon model to simulate man. J Med Primatol. 1972;1(3):132–141. doi: 10.1159/000460376. [DOI] [PubMed] [Google Scholar]
  27. Tremoli E., Morazzoni G., Maderna P., Colli S., Paoletti R. Studies on the antithrombotic action of Boc-D-Phe-Pro-Arg-H (Gyki 14,451). Thromb Res. 1981 Sep 15;23(6):549–553. doi: 10.1016/0049-3848(81)90178-x. [DOI] [PubMed] [Google Scholar]
  28. WEISMANN R. E., TOBIN R. W. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg. 1958 Feb;76(2):219–227. doi: 10.1001/archsurg.1958.01280200041005. [DOI] [PubMed] [Google Scholar]
  29. White P. W., Sadd J. R., Nensel R. E. Thrombotic complications of heparin therapy: including six cases of heparin--induced skin necrosis. Ann Surg. 1979 Nov;190(5):595–608. doi: 10.1097/00000658-197911000-00007. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES